Filing Details

Accession Number:
0000947871-22-000675
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-31 16:36:35
Reporting Period:
2022-05-26
Accepted Time:
2022-05-31 16:36:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1699382 Pmv Pharmaceuticals Inc. PMVP () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022-4629
No No Yes No
1615374 Orbimed Capital Gp V Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022-4629
No No Yes No
1808744 Orbimed Genesis Gp Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022-4629
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-05-26 26,253 $15.93 87,786 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,475,291 Indirect See Footnotes
Footnotes
  1. Represents the sale of shares of the Issuer's common stock ("Shares"), which was effected after market close on May 26, 2022.
  2. These Shares were sold in multiple transactions at prices ranging from $15.55 to $16.09. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.
  3. The Shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
  4. The Shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.4.
  5. This report on Form 4 is jointly filed by OrbiMed Advisors, GP V and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.